Keyphrases
CARMN
100%
Therapeutic Targeting
100%
Long Non-coding RNA (LncRNA)
100%
Vascular Smooth muscle Cells
80%
Plaque Growth
30%
Dedifferentiation
10%
RNA Delivery
10%
Pathological Transition
10%
Therapeutic Role
10%
Synthetic Phase
10%
Atherosclerosis Prevention
10%
Atheroma
10%
Conventional Medication
10%
Cellular Homeostasis
10%
Cell Plasticity
10%
Pathological Phenotype
10%
Cardiovascular Therapy
10%
Advance Treatment
10%
Phenotypic Switching
10%
Specific Delivery
10%
Promising Strategies
10%
Monocytes
10%
New Therapies
10%
Vascular Tone
10%
Nanoparticles
10%
Pharmacological Agents
10%
Immune Evasion
10%
Vasculature
10%
Dysregulation
10%
Plaque
10%
Pharmacokinetics
10%
Structural Integrity
10%
Nanomedicine
10%
Adverse Reactions
10%
Cardiovascular Disease
10%
Risk Factors
10%
United States
10%
Therapeutic Efficacy
10%
Therapeutic Potential
10%
Successful Completion
10%
Managing Risk
10%
Molecular Targets
10%
Vascular Disease
10%
Still Face
10%
Low Efficiency
10%
Pharmacology, Toxicology and Pharmaceutical Science
Long Untranslated RNA
100%
Atherosclerosis
100%
Combination Therapy
22%
Cardiovascular Disease
22%
Vascular Disease
11%
Atheroma
11%
Adverse Event
11%
Nanoparticle
11%
Pharmacokinetics
11%
Nanomedicine
11%
Molecular Target
11%